Publications by authors named "Ana Florez-Vela"

Background: Low-cardiac output syndrome (LCOS) after cardiac surgery secondary to systemic hypoperfusion is associated with a higher incidence of renal and neurological damage. A range of effective therapies are available for LCOS. The beneficial systemic effects of levosimendan persist even after cardiac output is restored, which suggests an independent cardioprotective effect.

View Article and Find Full Text PDF

Purpose: To evaluate if the preoperative administration of levosimendan in patients with right ventricular (RV) dysfunction, pulmonary hypertension, and high perioperative risk would improve cardiac function and would also have a protective effect on renal and neurological functions, assessed using two biomarkers neutrophil gelatinase-associated lipocalin (N-GAL) and neuronal enolase.

Methods: This is an observational study. Twenty-seven high-risk cardiac patients with RV dysfunction and pulmonary hypertension, scheduled for cardiac valve surgery, were prospectively followed after preoperative administration of levosimendan.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Ana Florez-Vela"

  • Ana Florez-Vela's research primarily focuses on the effects of levosimendan administration in patients undergoing cardiac surgery, specifically in relation to low cardiac output syndrome and right ventricular dysfunction.
  • Her studies highlight the cardioprotective benefits of levosimendan, suggesting it offers not only improved cardiac function but also protective effects on renal and neurological health, as indicated by biomarkers such as neutrophil gelatinase-associated lipocalin and neuronal enolase.
  • The findings from her clinical trials and observational studies demonstrate that early intervention with levosimendan can lead to better postoperative outcomes in high-risk cardiac patients, emphasizing its potential role in enhancing overall patient safety and recovery.